Abstract：Objective To investigate the clinical effect of Maiguan Fukang Capsules in the adjuvant treatment of acute cerebral infarction. Methods A total of 60 patients with acute cerebral infarction admitted to the Department of Encephalopathy, Bozhou Hospital of Traditional Chinese Medicine in Anhui Province from March 2019 to November 2020 were selected. By pre-creating randomized even and odd sequences, they were divided into control group and treatment group, with 30 patients in each group. The control group was treated with Aspirin Enteric-coated Tablets, Atorvastatin Calcium Tablets and Butylphthalide Soft Capsules, and the treatment group was treated with Maiguan Fukang Capsules on the basis of the control group. The course of treatment was two weeks. The changes of clinical response rate, traditional Chinese medicine syndrome score, National Institute of Health stroke scale (NIHSS) score, activity of daily living (Barthel index), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), angiotensin-1 (Ang-1), and homocysteine (Hcy) levels were compared between two groups before and after treatment. Adverse events during treatment were recorded in both groups. Results The clinical efficacy of the treatment group was better than that of the control group, and the difference was statistically significant (P ＜ 0.05). Before treatment, there were no significant differences in traditional Chinese medicine syndrome score, NIHSS score, Barthel index, hs-CRP, IL-6, Ang-1, and Hcy levels between the two groups (P ＞ 0.05). After treatment, traditional Chinese medicine syndrome score, NIHSS score, hs-CRP, IL-6, Ang-1, and Hcy levels in the two groups were significantly lower than before treatment, and Barthel index was significantly higher than before treatment, and traditional Chinese medicine syndrome score, NIHSS score, hs-CRP, IL-6, Ang-1, and Hcy levels in the treatment group were lower than those in the control group, the Barthel index was significantly higher than that of the control group, and the differences were highly statistically significant (P ＜ 0.01). There were no serious adverse reactions in both groups. Conclusion Maiguan Fukang Capsules has definite curative effect in the treatment of acute cerebral infarction and is worthy of clinical promotion.
何道胜 周会 李良勇 霍星星 马奎军▲. 脉管复康胶囊辅助治疗急性脑梗死的临床效果[J]. 中国医药导报, 2022, 19(14): 60-64.
HE Daosheng ZHOU Hui LI Liangyong HUO Xingxing MA Kuijun▲. Clinical effect of Maiguan Fukang Capsules in the adjuvant treatment of acute cerebral infarction. 中国医药导报, 2022, 19(14): 60-64.
京公网安备 11010502046598号